Findings

What do systematic reviews say?

2,234 questions · 2,325 findings · 216 reviews · Airways

Sort:Best matchNewestHighest certainty Download CSV

No studies found 249 · 10.7%GRADE not reported 107 · 4.6%Very low 276 · 11.9%Low 751 · 32.3%Moderate 718 · 30.9%High 224 · 9.6%

Benralizumab 100 mg vs placebo

Serious adverse events · patients with chronic obstructive pulmonary disease

Benralizumab 100 mg showed no clear difference in serious adverse events compared with placebo (moderate certainty).

1 finding from 1 review

Anti‐IL‐5 therapies for chronic obstructive pulmonary disease 2020 · Cochrane Headline outcomes only
Odds ratio 0.9 [0.75, 1.08]
3 studies · 2333 participants
Moderate

Benralizumab 100 mg vs placebo

Change in SGRQ total score · patients with chronic obstructive pulmonary disease

1 finding from 1 review

Anti‐IL‐5 therapies for chronic obstructive pulmonary disease 2020 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 1433 participants
High

Benralizumab 100 mg vs placebo

QoL · patients with chronic obstructive pulmonary disease

1 finding from 1 review

Anti‐IL‐5 therapies for chronic obstructive pulmonary disease 2020 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 1351 participants
High

Benralizumab 100 mg vs placebo

Lung function (FEV₁) · patients with chronic obstructive pulmonary disease

1 finding from 1 review

Anti‐IL‐5 therapies for chronic obstructive pulmonary disease 2020 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 1425 participants
High

Mepolizumab 100 mg vs placebo

Time to first moderate or severe exacerbation All participants · patients with chronic obstructive pulmonary disease

Mepolizumab 100 mg showed no clear difference in time to first moderate or severe exacerbation All participants compared with placebo (moderate certainty).

1 finding from 1 review

Anti‐IL‐5 therapies for chronic obstructive pulmonary disease 2020 · Cochrane Headline outcomes only
Hazard ratio 0.87 [0.75, 1]
2 studies · 1285 participants
Moderate

Benralizumab 100 mg vs placebo

Lung function (FEV₁) Eosinophils ≥ 220/μL · patients with chronic obstructive pulmonary disease

1 finding from 1 review

Anti‐IL‐5 therapies for chronic obstructive pulmonary disease 2020 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 1334 participants
Moderate

Mepolizumab 100 mg vs placebo

Rate of exacerbations with ED visit or hospitalisations Eosinophilic phenotype · patients with chronic obstructive pulmonary disease

Mepolizumab 100 mg showed no clear difference in rate of exacerbations with ED visit or hospitalisations Eosinophilic… compared with placebo (moderate certainty).

1 finding from 1 review

Anti‐IL‐5 therapies for chronic obstructive pulmonary disease 2020 · Cochrane Headline outcomes only
Rate ratio 0.9 [0.65, 1.24]
2 studies · 911 participants
Moderate

Mepolizumab 100 mg vs placebo

Rate of exacerbations requiring emergency department treatment or admission · patients with chronic obstructive pulmonary disease

Mepolizumab 100 mg showed no clear difference in rate of exacerbations with ED visit or hospitalisations All… compared with placebo (moderate certainty).

1 finding from 1 review

Anti‐IL‐5 therapies for chronic obstructive pulmonary disease 2020 · Cochrane Headline outcomes only
Rate ratio 0.94 [0.72, 1.22]
2 studies · 1285 participants
Moderate

Mepolizumab 100 mg vs placebo

Serious adverse events · patients with chronic obstructive pulmonary disease

Mepolizumab 100 mg showed no clear difference in serious adverse events compared with placebo (moderate certainty).

1 finding from 1 review

Anti‐IL‐5 therapies for chronic obstructive pulmonary disease 2020 · Cochrane Headline outcomes only
Odds ratio 0.82 [0.65, 1.05]
2 studies · 1285 participants
Moderate

Mepolizumab 100 mg vs placebo

QoL · patients with chronic obstructive pulmonary disease

1 finding from 1 review

Anti‐IL‐5 therapies for chronic obstructive pulmonary disease 2020 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 911 participants
Moderate

Mepolizumab 100 mg vs placebo

Change in SGRQ total score · patients with chronic obstructive pulmonary disease

1 finding from 1 review

Anti‐IL‐5 therapies for chronic obstructive pulmonary disease 2020 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 1285 participants
Moderate

Myofunctional therapy vs sham

Daytime sleepiness (ESS): endpoint score. · obstructive sleep apnoea

1 finding from 1 review

Myofunctional therapy (oropharyngeal exercises) for obstructive sleep apnoea 2020 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 82 participants
Moderate

Myofunctional therapy vs continuous positive airway pressure (CPAP)

AHI · obstructive sleep apnoea

1 finding from 1 review

Myofunctional therapy (oropharyngeal exercises) for obstructive sleep apnoea 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 54 participants
Low

Myofunctional therapy vs continuous positive airway pressure (CPAP)

Snoring frequency: endpoint score. · obstructive sleep apnoea

1 finding from 1 review

Myofunctional therapy (oropharyngeal exercises) for obstructive sleep apnoea 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 54 participants
Low

Myofunctional therapy vs continuous positive airway pressure (CPAP)

Snoring intensity: endpoint score. · obstructive sleep apnoea

1 finding from 1 review

Myofunctional therapy (oropharyngeal exercises) for obstructive sleep apnoea 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 54 participants
Low

Myofunctional therapy vs CPAP + Myofunctional therapy

Daytime sleepiness (ESS): endpoint score. · obstructive sleep apnoea

1 finding from 1 review

Myofunctional therapy (oropharyngeal exercises) for obstructive sleep apnoea 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 49 participants
Low

Myofunctional therapy vs CPAP + Myofunctional therapy

AHI · obstructive sleep apnoea

1 finding from 1 review

Myofunctional therapy (oropharyngeal exercises) for obstructive sleep apnoea 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 49 participants
Low

Myofunctional therapy vs CPAP + Myofunctional therapy

Snoring frequency: endpoint score. · obstructive sleep apnoea

1 finding from 1 review

Myofunctional therapy (oropharyngeal exercises) for obstructive sleep apnoea 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 49 participants
Low

Myofunctional therapy vs CPAP + Myofunctional therapy

Snoring intensity: endpoint score. · obstructive sleep apnoea

1 finding from 1 review

Myofunctional therapy (oropharyngeal exercises) for obstructive sleep apnoea 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 49 participants
Low

Myofunctional therapy vs respiratory exercises + nasal dilator strip

Daytime sleepiness (ESS): endpoint score. · obstructive sleep apnoea

1 finding from 1 review

Myofunctional therapy (oropharyngeal exercises) for obstructive sleep apnoea 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 58 participants
Low